文献速递临床微生物分子诊断质量管理与危急值

结核分枝杆菌复合群利福平药敏试验折点定义不当的后果

On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex.
PubMed 文献 · J Clin Microbiol · 2021-03-19

本文评述WHO将Middlebrook 7H10和MGIT 960系统的利福平临界浓度从1 μg/ml降至0.5 μg/ml,指出旧折点导致其他药敏方法折点偏高及7种rpoB边缘耐药突变解读困惑。同期Shea等研究提示CLSI为Sensititre MYCOTB系统认可的折点可能也偏高,强调药敏方法需以严格定义的参考标准校准并常规应用NGS。

要点

  • WHO将7H10和MGIT 960的利福平临界浓度从1 μg/ml降至0.5 μg/ml。
  • 旧折点作为事实参考标准导致其他药敏方法折点偏高。
  • 7种rpoB边缘耐药突变的解读存在困惑。

核心结论

  • 利福平药敏试验折点定义不当可导致其他方法折点偏高和耐药突变解读困惑。
  • 药敏方法需以严格定义的参考标准校准,并常规应用NGS调查不一致结果。

研究设计与样本

  • 本文为针对近期系统综述和Shea等研究的评述文章。
  • Shea等研究提供了CLSI为Sensititre MYCOTB系统认可的折点可能偏高的证据。

主要发现

  • WHO将7H10和MGIT 960的利福平临界浓度从1 μg/ml降至0.5 μg/ml。
  • 旧7H10折点使用超过半个世纪,作为事实参考标准导致其他药敏方法折点偏高。
  • 旧折点导致7种rpoB边缘耐药突变(L430P、D435Y、H445L、H445N、H445S、L452P、I491F)解读困惑。
  • CLSI为Sensititre MYCOTB系统认可的折点可能也偏高。

关键数值与推荐

  • WHO将7H10和MGIT 960的利福平临界浓度从1 μg/ml降至0.5 μg/ml。
  • 7种rpoB边缘耐药突变为L430P、D435Y、H445L、H445N、H445S、L452P和I491F。

临床怎么用

  • 药敏试验方法应以严格定义的参考标准进行校准。
  • 对不一致的药敏结果可常规应用下一代测序进行调查。
  • 关注MYCOTB系统折点可能偏高的问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In a recent report of a systematic review of critical concentrations (CCs), the World Health Organization (WHO) lowered the rifampin (RIF) CC for antimicrobial susceptibility testing (AST) of the Mycobacterium tuberculosis complex using Middlebrook 7H10 medium and the Bactec Mycobacterial Growth Indicator Tube (MGIT) 960 system from 1 to 0.5 μg/ml. The previous RIF CC for 7H10 had been in use for over half a century. Because it had served as the de facto reference standard, it contributed to the endorsement of inappropriately high CCs for other AST methods, including the U.S. Food and Drug Administration (FDA)-approved MGIT system. Moreover, this resulted in confusion about the interpretation of seven borderline resistance mutations in rpoB (i.e., L430P, D435Y, H445L, H445N, H445S, L452P, and I491F). In this issue of the Journal of Clinical Microbiology, Shea et al. (J Clin Microbiol 59:e01885-20, 2021, https://doi.org/10.1128/JCM.01885-20) provide evidence that the CC endorsed by the Clinical and Laboratory Standards Institute for the Sensititre MYCOTB system, which is not FDA approved but is CE-IVD marked in the European Union, is likely also too high. These findings underscore the importance of calibrating AST methods against a rigorously defined reference standard, as recently proposed by the European Committee on Antimicrobial Susceptibility Testing, as well as the value of routine next-generation sequencing for investigating discordant AST results.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Köser CU, Georghiou SB, Schön T, et al. On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex. J Clin Microbiol. 2021. PMID: 33568463. doi:10.1128/JCM.02328-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。